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The aim of the present study was to analyse lymphocyte subsets in consecutive peripheral blood samples and consecutive
tumour tissue core needle biopsies performed before and during interleukin-2 based immunotherapy, and to correlate the
ﬁndings with objective response and survival. Twenty-six patients with metastatic renal cell carcinoma were treated with low
dose s.c. interleukin-2, interferon-a and histamine. A total of 250 blood samples and 62 core needle biopsies from 23 and 19
of these patients, respectively, were analysed. After 2 weeks of treatment, a signiﬁcant positive correlation between absolute
number of peripheral blood lymphocytes (P=0.028), CD3 (P=0.017), CD57 (P=0.041) and objective response was
demonstrated. There was no correlation between any peripheral blood leukocyte subsets and survival. Cytotoxicity of
peripheral blood mononuclear cells was not correlated to objective response or survival. Within the tumour tissue at baseline,
a signiﬁcant positive correlation between CD4 (P=0.027), CD8 (P=0.028), CD57 (P=0.007) and objective response was
demonstrated. After one month of immunotherapy, a signiﬁcant positive correlation between intratumoral CD3 (P=0.026),
CD8 (P=0.015), CD57 (P=0.009) and objective response was demonstrated. A signiﬁcant positive correlation between
intratumoral baseline CD4 (P=0.047), baseline CD57 (P=0.035), CD3 at one month (P=0.049) and survival was
demonstrated. These data provide novel in vivo evidence of the possible contribution of lymphocyte subsets in the tumour
reduction in responding patients during interleukin-2 based immunotherapy. Conﬁrmation of the results requires further
studies including a larger number of patients.
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Manipulating the immune system by interleukin-2 (IL-2) based
immunotherapy may induce durable tumour regression in meta-
static renal cell carcinoma (mRCC) (Minasian et al, 1993; Fyfe et
al, 1995; Jeal and Goa, 1997; Bordin et al, 2000; Fisher et al,
2000; Negrier et al, 2000). However, only a minority of patients
beneﬁt from treatment and consequently, many efforts have been
made to assess parameters, which may predict objective response
and survival in order to select those patients who most likely will
beneﬁt from treatment.
Our understanding of the mechanisms by which IL-2 and inter-
feron-alpha (IFN-a) mediate their antineoplastic actions is
incomplete. Based on peripheral blood sample analyses during
the last 15 years, it is still unclear whether lymphocyte subsets
during immunomodulative therapy in mRCC have an impact on
objective response and survival (Bukowski, 1997; Jeal and Goa,
1997; Hernberg, 1999). Several studies have demonstrated increased
number of lymphocytes (Palmer et al, 1993; Lissoni et al, 1994;
Bordin et al, 2000), lymphocyte subsets (Wersall and Mellstedt,
1995; Gohring et al, 1996) including natural killer (NK-) cells
(Atzpodien et al, 1993; von Rohr et al, 1993) and increased cyto-
toxicity (von Rohr et al, 1993; Wersall and Mellstedt, 1995) in
responding patients during immunotherapy, but no consistent
ﬁndings have been demonstrated (Bukowski, 1997; Jeal and Goa,
1997). No peripheral blood lymphocyte subset has been correlated
to favourable survival. Moreover, knowledge about lymphocyte
subsets within metastatic tumour tissue is scarce. In mRCC, only
one study has focused on the immunological changes locally at
the site of metastatic tumour during immunotherapy (Bukowski
et al, 1997). In that study, however, biopsies were not performed
systematically and no signiﬁcant correlations to objective response
or survival were found.
In an attempt to identify predictive factors for objective response
and prognostic factors for survival, we have monitored lymphocyte
subsets in as well consecutive peripheral blood samples as consecu-
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Received 7 February 2002; revised 29 April 2002; accepted 8 May 2002
*Correspondence: F Donskov, Department of Oncology, Aarhus Univer-
sity Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark;
E-mail: fd@microbiology.au.dk
British Journal of Cancer (2002) 87, 194–201
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comtive tumour tissue core needle biopsies in patients with mRCC
undergoing immunotherapy with IL-2, IFN-a and histamine.
MATERIALS AND METHODS
Patients and samples
Twenty-six patients with metastatic renal cell carcinoma at the
Department of Oncology, Aarhus University Hospital were
enrolled in a multi-centre prospective phase II trial of s.c. IL-
2, IFN-a and histamine dihydrochloride between February 1999
and February 2000 (Donskov et al, 2002). The treatment plan
consisted of one priming-week of IFN-a and up to nine treat-
ment cycles of interferon-a (human leukocyte IFN-a, Interferon
Alfanative
1, BioNative, Sweden) 3.0 million IU as a ﬁxed dose,
s.c. once daily, 7 days per week throughout the study; inter-
leukin-2 (aldesleukin, rIL-2, Proleukin
1, Chiron, The Nether-
lands) 2.4 million IU per m
2, s.c., two times daily 5 days per
week, weeks 1 and 2 every month; and histamine dihydrochlor-
ide (Ceplene
TM, Maxim Pharmaceuticals Inc, San Diego, USA)
1.0 mg in 1.0 ml by 20 min slow s.c. injections, two times daily,
5 days per week throughout the study. The addition of histamine
was based on a new concept of how to increase the efﬁcacy of
IL-2 and IFN-a. However, by use of the present low dose regi-
men of IL-2 and IFN-a, histamine did not appear to add efﬁcacy
with respect to response (Donskov et al, 2002). Standard WHO
criteria were used for classifying objective response (Donskov et
al, 2002). All patients had clear cell carcinoma except one,
who had a papillary renal cell carcinoma. This patient achieved
stable disease (SD).
Of the 26 patients, 24 gave written informed consent for
consecutive blood samples and core needle biopsies. One patient
did not complete one course of therapy because of toxicity and
was not evaluable for response. This patient was excluded from
all further analysis. One patient was excluded from the core
needle biopsy analysis as he had only ﬁne needle biopsies
performed. Thus, a total of 23 patients were evaluable for conse-
cutive blood samples and 22 patients were evaluable for
consecutive core needle tumour biopsies. Patient characteristics
are given in Table 1.
Blood samples were obtained at baseline, before start of week 1,
2 and 3 and thereafter before start of every second week through-
out treatment. A total of 250 blood samples from 23 patients were
evaluated (Table 2a). Core needle biopsies (18G cutting needle)
were collected by standard ultrasound-guided procedures (Jennings
et al, 1989). Core needle biopsies were performed at baseline and
before start of weeks 5, 12, 19, 24, 31 and 36 if possible. A total
of 90 core needle biopsies in 22 patients were performed at differ-
ent metastatic sites (subcutis, pleura, abdominal muscle, abdominal
soft tissue, lymph node, liver and kidney). However, only 62 core
needle biopsies in 19 patients were evaluable (Table 2b). There
were three non-evaluable patients, two because of insufﬁcient
tumour tissue in the biopsies and one because of necrosis in all
biopsies at all time points. One patient had only a baseline biopsy
performed (withdrawal of consent). Nineteen of the 90 biopsies
(21%) were excluded because of necrosis. Moreover, in three of
four responding patients, by week 12 and at following biopsy time
points, tumour had disappeared (two patients) and biopsies
contained only ﬁbrotic materials (one patient). Thus, for the statis-
tical analyses, only biopsies performed at baseline and at week 5
were used.
Preparation of PBMCs
Peripheral blood mononuclear cells (PBMC) were isolated from
lithium-heparinzed whole blood samples by Ficoll-Paque (Pharma-
cia Biotech, Uppsala, Sweden) gradient separation, washed twice
and stored at 71358C until use.
Flow cytometry
Surface phenotypes were determined by ﬂow cytometry using a
Coulter XL-2 ﬂow cytometer (Coulter Electronics, UK). Data were
analysed using Flow-Jo software (Treestar, San Carlos, CA, USA).
Direct ﬂuorochrome-conjugated antibodies (FITC or PE) were
purchased from DAKO, Denmark (CD3, cat. no F0818; CD4,
cat. no. F0766; CD8, cat. no. R0806 and CD20, cat. no. F0799)
and Becton Dickinson, Denmark (CD56, cat. no. 347747 and
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Table 1 Baseline patient characteristics (n=23)
Median age, years (range) 55 (19–68)
Sex
Male 20 (87%)
Female 3 (13%)
Karnofsky performance status
100 7 (30%)
90 8 (35%)
80 4 (17%)
70 4 (17%)
Prior therapy
Nephrectomy 10 (44%)
Excision of metastatic lesions 5 (22%)
None 11 (48%)
Extent of disease (no. of organ sites)
1 2 (9%)
2 7 (30%)
3 4 (17%)
4 or more 10 (44%)
Sites of disease
Primary kidney tumor 13 (57%)
Local recurrence kidney bed 5 (22%)
Lung/pleura 12 (52%)
Lymph node 13 (57%)
Liver 5 (22%)
Bone 9 (39%)
Soft tissue 9 (39%)
Others 8 (35%)
MSKCC prognostic criteria*
Favourable 2 (9%)
Intermediate 11 (48%)
Poor 10 (44%)
*Memorial Sloan-Kettering Cancer Center (Motzer et al, 1999). Risk factors: Low
Karnofsky PS 580, LDH 51.5 times upper limit of normal, haemoglobin 5lower
limit of normal, corrected s-Ca410 mg dl
71 and no prior nephrectomy. No risk
factors=favourable prognosis (20 months median survival), 1–2 risk
factors=intermediate prognosis (10 months median survival) and 42 risk
factors=poor prognosis (4 months median survival)
Table 2a Number of performed consecutive blood samples
Week 0 1 23579 1 1 1 3 1 5 1 7 1 9 2 1 2 3 2 5 Total
Number 21 22 21 23 23 22 20 18 17 11 12 10 10 10 10 250
blood
samples
Table 2b Number of performed consecutive tumor tissue core needle
biopsies
Week 0 5 12 19 24 31 36 Total
Number performed biopsies/ 25/22 23/20 19/16 8/7 7/6 4/3 4/3 90/22
number of patients
Number evaluable biopsies/ 20/19 19/18 10/9 5/5 5/4 1/1 2/1 62/19
number of patients
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 194–201CD57, cat. no. 347393). DAKO isotype controls were murine IgG1/
FITC+IgG2a/RPE, cat. no. X 0949 and murine IgM/FITC, cat.no. X
0934. Leukogate was CD45/FITC+CD14 IgG2a/RPE, cat. no. FR
700, DAKO. A total of 2610
5 cells were incubated with antibody
for 15 min at room temperature in the dark, washed twice with
PBS containing 0.01% sodium azide and ﬁxed in 0.25% formalde-
hyde. Flow cytometry was performed within 24 h.
Cytotoxicity Assay
Cytolytic activity was determined by standard 4-h
51Cr-release
assays. K562 tumour target cell pellets were suspended in
100 mCi of
51Cr (cat. no. NEZ030S, Dupharma, Kastrup, Denmark)
and placed in a humidiﬁed incubator with 5% CO2 at 37ºC for
1 h. Target cells were then washed free of excess
51Cr and plated
in 96-well round-bottomed plate at 10
4 cells well
71. Effectors
(PBMC) were added to the wells at various effector-target ratios
(40:1, 20:1 and 10:1). Wells containing target cells were used
to determine spontaneous release. Wells containing target cells
were mixed 10 times by the pipette and used to determine maxi-
mum target
51Cr release. Assay plates were incubated at 37ºC
with 5% CO2 for 4 h. A gamma counter (Cobra Autogamma Pack-
ard, Canberra Company, UK) was used to measure the
radioactivity released from the lysed tumour cells. Per cent speciﬁc
release was calculated as 1006(Experimental release7spontaneous
release)/((Maximum release60.8)7spontaneous release). The
spontaneous release never exceeded 11% of the maximum release
(in most experiments 4–8%). All blood samples from one patient
were assayed within maximum 2 days.
Immunohistochemistry
Sections (2 mm) of formalin-ﬁxed, parafﬁn-embedded tissue were
mounted on ChemMate slides (DAKO, Denmark) and dried 1 h
at 60C. Following xylene deparafﬁnzation, rehydration through a
series of graded alcohol and endogenous peroxidase blocking
(0.5% hydrogen peroxidase in water for 30 min), antigen retrieval
was performed by microwave oven heating (365 min at 850 W in
Tris/EGTA retrieval buffer (pH 9.0)). Thereafter, slides were cooled
to room temperature and placed in TBS. The following antibodies
were used for 1 h of incubation: (a) CD3 (cat. no. A 0452, DAKO)
1:100; (b) CD4 (cat. no. NCL-CD4-1F6, NovoCastra) 1:50; (c)
CD8 (cat. no. M 7103, DAKO) 1:100; (d) CD20 (cat. no. M
0755, DAKO) 1:500; (e) CD56 (cat. No. NCL-CD56-1B6, Novo-
Castra), 1:40; (f) CD57 (cat. no. 33251A, Pharmingen) 1:500;
(g) CD79a (cat. no. M 7050, DAKO) 1:50. As second layer the
Horseradish Peroxidase EnVision polymer (catalogue number K
4000/K 4002, DAKO, Denmark) was used for 30 min of incuba-
tion. Staining were visualised with diaminobenzidine
tetrahydrochloride solution. Slides were counterstained in Mayer’s
haematoxylin and mounted with Aqutex (cat. no. 64912-50,
KEBO-lab, Denmark). All dilutions were made in Antibody Diluent
(cat. no. S 2022, DAKO). All staining were performed in a Tech-
mate automate machine. Some of the staining was split to two
staining sessions because of the amount of samples. A lymph node
was used as a positive control. As negative controls, substitution of
primary antibody with PBS and the following antibodies were used
(h) IgG1 (cat. no. 33811A, Pharmingen) 1:50; (i) IgG2a (cat. no.
33031A, Pharmingen) 1:500; (j) IgG2b (cat. no. 33801A, Pharmin-
gen) 1:500 and (k) IgM (cat. no. X 0942, DAKO) 1:20.
Measuring intratumoural immune cells
A stereological examination was performed using a morphometric
system consisting of a Olympus AH-3 microscope with a motor-
ized stage, controlled by a computer for manual interactive
counting on the computer screen (Gundersen et al, 1988). The
software used was CAST-GRID v 1.09, developed by Olympus,
Denmark. Each microscopic ﬁeld of vision was projected onto
the computer screen with a video camera, and the computer
generated an unbiased counting frame in which the measurements
were done. On the projected image of the section, the tumour
area was encircled. Necrosis, artifacts and ﬁbrous areas were
omitted. The ﬁrst ﬁeld of vision was chosen at random, thereafter,
the computer sampled systematically the following ﬁelds of vision
within the entire encircled area. A number of 40 ﬁelds (4951 mm
2
each) were counted. The entire core needle biopsy was assessed.
Only a cell with staining restricted to the plasma membrane, a
visible nucleus and located within the counting frame was
counted as positive. The mean number of cells per mm
2 tumour
tissue was assessed for each patient. Staining was analysed blinded
by one observer. For testing the reproducibility, CD3 and CD57
sections were ranked according to their number of immune cells
and every eighth case was selected and counted blinded by a
senior histopathologist (NM). A high level of reproducibility
(Spearman’s rho=0.9, P50.0001) was found.
Statistics
Results are expressed as median values. The relationship between
baseline and on-treatment lymphocyte subsets and objective
response was evaluated using the nonparametric Kruskal–Wallis
test, followed by the Mann–Whitney rank-sum test for trend
across ordered groups if appropriate. The relationship between
baseline and on-treatment lymphocyte subsets and survival was
evaluated using the method of Kaplan–Meier and the log-rank
test. Dichotomy of the patients was done at the median value for
each evaluated parameter. The median follow-up period was 32.3
months, (range 24.1–36.0 months). The survival data were
updated 30th January 2002.
All reported P-values are two-sided. Statistical analyses were
performed using SPSS v10.0.
RESULTS
Clinical treatment results
A total of 23 patients treated with low dose IL-2, IFN-a and hista-
mine were evaluable for consecutive blood samples and tumour
biopsies. Of these, four patients achieved partial remission (PR),
eight patients achieved stable disease (SD) and 11 patients had
progressive disease (PD). Median survival was 12.5 months (range
3.8733.8+ months). Three patients (two with PR and one with
SD) had no evidence of disease and were alive at 32.9+, 26.6+
and 33.8+ months, respectively, after subsequent resection of resi-
dual tumours. At the time of analysis, 17 patients had died, giving
a censoring rate of 26.1%.
Correlation between number of peripheral blood
lymphocyte subsets and objective response
Baseline and on-treatment absolute number of lymphocytes and
lymphocyte subsets deﬁned by ﬂow cytometry were examined
and compared to responding (PR) and non-responding (SD+PD)
patients. At baseline, no signiﬁcant differences in responding
patients compared to non-responding patients were demonstrated.
Changes from baseline in the absolute number of lymphocytes and
CD3 T-cells were detected in all patients. After 2 weeks of treat-
ment, the absolute number of lymphocytes (P=0.028), CD3 T-
cells (P=0.017) and CD57 NK cells (P=0.041) was signiﬁcantly
higher in responding patients compared with non-responding
patients, Figure 1. No differences in responding and non-respond-
ing patients were seen after 2 and 4 weeks of treatment in absolute
number of CD4 helper T-cells (P=0.11), CD8 cytotoxic T-cells
(P=0.061), CD20 B-cells (P=0.31) and CD56 NK-cells (P=0.61),
Figure 1.
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median PD
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E: CD20
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F: CD56
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G: CD57
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Figure 1 Monitoring of peripheral blood lymphocytes and lymphocyte subsets during interleukin-2 based immunotherapy. Median values for patients with
partial responses (PR), stable disease (SD) and progressive disease (PD) are shown for (A): lymphocytes, (B): T-cells (CD3), (C): cytotoxic T-cells (CD8),
(D): helper T-cells (CD4), (E): B-cells (CD20), (F): CD56 NK-cells and (G): CD57 NK-cells, respectively. Vertical and horizontal axes, 10
9 cells l
71 and
weeks during immunotherapy, respectively.
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response
NK cell cytotoxicity deﬁned by
51Chromium-release assay was
monitored before and during therapy, Figure 2. When cytotoxicity
of responding and non-responding patients at baseline and during
therapy was compared, no signiﬁcant differences were noted.
However, whereas cytotoxicity of PD patients remained at the same
level of about 20% during treatment, cytotoxicity of non-PD
(PR+SD) patients increased signiﬁcantly at week 7 (P=0.03) and
week 11 (P=0.033) compared with PD patients.
Correlation between number and activity of peripheral
blood lymphocyte subsets and survival
NK cell cytotoxicity, baseline and on-treatment absolute number of
peripheral blood lymphocytes and lymphocyte subsets were exam-
ined and compared with survival. However, no signiﬁcant
correlations to survival were demonstrated (data not shown).
Correlation between intratumoural lymphocyte subsets
and objective response
Baseline and on-treatment intratumoural lymphocyte subsets
deﬁned by immunohistochemistry were evaluated and correlated
to objective response. At baseline, the number of CD4 cells per
mm
2 tumour tissue was signiﬁcantly higher (P=0.027) in respond-
ing (PR) patients compared with non-responding (SD+PD)
patients, Figure 3. Moreover, the number of CD8 cells per mm
2
tumour tissue and CD57 cells per mm
2 tumour tissue at baseline
was signiﬁcantly higher (P=0.028 and P=0.007 respectively) in
responding patients compared with non-responding patients. The
number of intratumoral B-cells (CD20), plasma cells (CD79-a)
and CD56 NK-cells were low, both at baseline and during treat-
ment, and were not signiﬁcantly correlated to objective response,
Figure 3.
After 1 month of therapy, the number of CD3 cells per mm
2
tumour tissue was signiﬁcantly higher (P=0.026) in responding
patients compared with non-responding patients. Moreover, the
number of CD8 cells per mm
2 tumour tissue and CD57 cells
mm
2 tumour tissue were signiﬁcantly higher (P=0.015 and
P=0.009, respectively) in responding patients compared with
non-responding patients.
A clear cell-to-cell contact between immune effector cells and
tumour target cells was noted in biopsies during immunotherapy,
Figure 4.
Correlation between tumour-inﬁltrating
lymphocyte-subsets and survival
We also studied the inﬂuence of intratumoural lymphocyte subsets
on survival. Intratumoural baseline CD4 (P=0.047), baseline CD57
(P=0.035) and one month CD3 (P=0.049) were all statistically
signiﬁcantly associated to survival, Figure 5. Median survival of
patients with 524 CD4 cells per mm
2 tumour tissue at baseline
was 22.2 months compared to 8.9 months for patients with 524
CD4 cells per mm
2 tumour tissue. For patients with more or less
than 50 CD57 cells per mm
2 tumour tissue at baseline, median
survival was 18.4 months and 8.9 months, respectively. Further-
more, median survival of patients with 5429 CD3 cells per mm
2
tumour tissue after one month of therapy was 22.2 months
compared to 11.5 months for patients with 5429 CD3 cells per
mm
2 tumour tissue. The numbers of intratumoral CD20, CD79-
a and CD56 were not correlated to survival.
DISCUSSION
This is to our knowledge the ﬁrst study in patients with mRCC
undergoing IL-2 based immunotherapy that demonstrates positive
correlation between number of intratumoral lymphocyte subsets
and both objective response and survival. Moreover, we demon-
strate that the composition of peripheral blood lymphocyte
subsets reﬂects the composition of intratumoral lymphocyte
subsets. However, more detailed information is obtained from
the intratumoral studies.
Little is known about how an effective antitumor response is
orchestrated. Our results demonstrate that immune effector cells
localise to sites of tumour in responding patients and that both
CD4 and CD8 T-cell subsets are requisite for the response to IL-
2 based immunotherapy. This is in accordance with ﬁndings in
metastatic malignant melanoma treated with IL-2 (Rubin et al,
1989) and IFN-a (Hakansson et al, 1996; 2001). Thus, there seems
to be a causative relationship between intratumoral lymphocyte
subsets and both response and survival, as indicated by the fact
that progressing patients had very few intratumoral lymphocyte
subsets at both baseline and during treatment. On the other hand,
our results should primarily be considered as hypotheses genera-
tion although all tested parameters were predeﬁned.
Consequently, our results have to be conﬁrmed in subsequent
studies.
NK cells are believed to contribute to the clinical efﬁcacy of
cancer immunotherapy using IL-2 in humans (Brittenden et al,
1996). However, NK cells show phenotypic heterogeneity in the
peripheral blood (Jonges et al, 2001). Thus, the CD56 molecule
is present on almost all NK cells, whereas the CD57 molecule is
only present on a subpopulation of the total NK cells (Brittenden
et al, 1996; Jonges et al, 2001). It is suggested that the CD57 anti-
gen is only present in a mature subset of NK cells (Garcia-Sanz et
al, 1996). Although there were no detectable intratumoral CD56
cells at baseline or during immunotherapy, as also reported in
metastatic malignant melanoma (Rubin et al, 1989), we demon-
strated that mononuclear cells expressing the CD57 molecule in
both peripheral blood and tumour tissue were requisite for
response. In addition, baseline intratumoural CD57 did inﬂuence
on survival. Presence of intratumoral CD57 cells was also asso-
ciated with favourable survival in studies of colorectal cancer
(Coca et al, 1997) and gastric cancer (Ishigami et al, 2000).
Only few studies have monitored the in vivo cytotoxicity of NK
cells during immunotherapy. To our knowledge, all studies have
failed to detect any signiﬁcant differences in K562-cytotoxicity
between responding and non-responding patients, as our study also
did. A few trials, however, have reported increased LAK cell activity
in responding patients compared to non-responding patients
(Krigel et al, 1990; von Rohr et al, 1993; Wersall and Mellstedt,
1995).
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Figure 2 Cytotoxicity against K562 targets for patients with partial re-
sponse (PR), stable disease (SD) and progressive disease (PD). Data points
represent median cytotoxicity at an effector:target ratio of 40:1.
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body-forming plasma cells were only present in peripheral blood
and tumour tissue at low levels and were not correlated with
response or survival. This ﬁnding was in accordance with most
other studies (Bukowski, 1997; Bukowski et al, 1997) except a
single study by Gohring et al (1996) demonstrating that baseline
number of peripheral blood B-cells correlated with clinical
response.
Our study suggests that tumour accumulation of speciﬁc
immune cells (T cells) and non-speciﬁc immune cells (CD57 NK
cells) were requisite for both objective response and survival. Thus,
an effective antitumor response might be orchestrated with partici-
pation of cells with different functions and from different parts of
the immune system.
All statistical differences in peripheral blood and tumour tissue
lymphocyte subsets have the same direction, and it is thus unlikely
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Figure 3 Intratumoural immune cells as predictors of response in patients with metastatic renal cell carcinoma at baseline (white bars) and after 1 month
of treatment (black bars) with interleukin-2, interferon-alpha and histamine. (A): T-cells (CD3), (B): helper T-cells (CD4), (C): cytotoxic T-cells (CD8), (D):
B-cells (CD20), (E) plasma cells (CD79-a), (F): CD56 NK-cells and (G): CD57 NK-cells. Horizontal and vertical axes, response to therapy and median
number of cells per mm
2 tumour tissue, respectively.
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sons.
In order to avoid sampling bias in measuring intratumoral
immune cells, we used stereological examination (Gundersen et
al, 1988), although most immunohistochemistry studies have used
semiquantitive scoring techniques. Using this random and systema-
tic sampling technique with an unbiased counting frame, a high
level of reproducibility was found, as has also been demonstrated
by others (Gundersen et al, 1988; Hansen et al, 1998). However,
this technique is associated with considerable workload and time
consumption. A special problem should be mentioned. Whereas
patients with PD had very few and easily detectable intratumoural
lymphocyte subsets, responding patients had large numbers of
lymphocyte subsets, which in several cases made enumerations
difﬁcult. Moreover, whereas tumours in patients with PD remained
unchanged, tumours in responding patients loosened and ﬁbrotic
areas developed. According to our counting rules, necrotic and
ﬁbrotic areas were avoided and only a cell with staining restricted
to the plasma membrane, a visible nucleus and located within the
counting frame was counted as positive. Thus, we may have under-
estimated the immune inﬁltrate in responding patients.
Differences in immunohistochemistry techniques, antibodies
used, assay sensitivity and laboratory skills may inﬂuence the stain-
ing results. Consequently, only well-known and commercially
available antibodies were used. Moreover all immunostainings were
performed in an automatic staining machine and a two-layer EnVi-
sion technique was used, thereby allowing all slides stained in one
or two turns. Thus, day-to-day variation was reduced and variation
contributed by laboratory processing was minimized.
One of the main difﬁculties in interpreting studies on lympho-
cyte subsets and natural cytotoxicity in patients with cancer is the
wide biologic variation existing in lymphocyte subsets number and
activity in patients and healthy controls. Therefore, to make mean-
ingful comparisons a larger number of subjects are required. In the
present study, 24 out of 26 treated patients (92%) gave written
informed consent for consecutive core needle biopsies and blood
samples. Nineteen patients (79%) had evaluable biopsies. In
comparison, Bukowski et al (1997) performed needle biopsies or
open biopsies from 17 out of 36 treated patients (47%) during
immunotherapy. Rubin et al (1989) performed biopsies on 82
patients but only 48 patients (59%) had evaluable biopsies. Thus,
we succeeded to include a high frequency of patients into the
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Figure 5 Intratumoural immune cells as prognostic factors for survival.
Kaplan–Meier plots concerning survival according to (A): intratumoural
baseline helper T-cells (CD4), (B): intratumoural baseline CD57+ natural
killer cells and (C): intratumoural one-month T-cells (CD3) in patients with
metastatic renal cell carcinoma treated with interleukin-2, interferon-a and
histamine. Cutoff points were median values for each parameter. Vertical
and horizontal axes, the survival probability and months of follow-up,
respectively.
Figure 4 Intratumoural accumulation of CD3 T-cells in a responding
patient after one month of immunotherapy. A clear cell-to-cell contact
between CD3 T-cells (brown staining restricted to the plasma membrane)
and tumour target cells (diffusely cytoplasmic brown staining) was noted.
Magniﬁcation640.
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British Journal of Cancer (2002) 87(2), 194–201 ã 2002 Cancer Research UKbiopsy part of the study. Despite that, it should be emphasized that
our results are based on very few patients, including only four
partial and no complete responders.
In conclusion, these data provide novel in vivo evidence of the
possible contribution of lymphocyte subsets in the tumour reduc-
tion in responding patients during interleukin-2 based
immunotherapy. Conﬁrmation of the results requires further
studies including a larger number of patients.
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